keyword
MENU ▼
Read by QxMD icon Read
search

Progression-free survival

keyword
https://www.readbyqxmd.com/read/29792754/loss-of-chromosome-18q11-2-q12-1-is-predictive-for-survival-in-patients-with-metastatic-colorectal-cancer-treated-with-bevacizumab
#1
Erik van Dijk, Hedde D Biesma, Martijn Cordes, Dominiek Smeets, Maarten Neerincx, Sudipto Das, Paul P Eijk, Verena Murphy, Anna Barat, Orna Bacon, Jochen H M Prehn, Johannes Betge, Timo Gaiser, Bozena Fender, Gerrit A Meijer, Deborah A McNamara, Rut Klinger, Miriam Koopman, Matthias P A Ebert, Elaine W Kay, Bryan T Hennessey, Henk M W Verheul, William M Gallagher, Darran P O'Connor, Cornelis J A Punt, Fotios Loupakis, Diether Lambrechts, Annette T Byrne, Nicole C T van Grieken, Bauke Ylstra
Purpose Patients with metastatic colorectal cancer (mCRC) have limited benefit from the addition of bevacizumab to standard chemotherapy. However, a subset probably benefits substantially, highlighting an unmet clinical need for a biomarker of response to bevacizumab. Previously, we demonstrated that losses of chromosomes 5q34, 17q12, and 18q11.2-q12.1 had a significant correlation with progression-free survival (PFS) in patients with mCRC treated with bevacizumab in the CAIRO2 clinical trial but not in patients who did not receive bevacizumab in the CAIRO trial...
May 24, 2018: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/29792289/combined-transarterial-chemoembolization-and-microwave-ablation-versus-transarterial-chemoembolization-in-bclc-stage-b-hepatocellular-carcinoma
#2
Rusi Zhang, Lujun Shen, Long Zhao, Zhaoming Guan, Qifeng Chen, Wang Li
PURPOSE: We aimed to compare the clinical effectiveness of combination therapy of transarterial chemoembolization (TACE) and microwave ablation (MWA) with TACE monotherapy in BCLC stage B HCC patients with tumor size ≤7 cm and tumor number ≤5. METHODS: We retrospectively reviewed 150 BCLC stage B HCC patients who had received TACE monotherapy or TACE-MWA combination therapy in our hospital from March 2007 to April 2016. The patients were matched by propensity score at the ratio of 1:2 by optimal method...
May 24, 2018: Diagnostic and Interventional Radiology: Official Journal of the Turkish Society of Radiology
https://www.readbyqxmd.com/read/29791475/ten-year-experience-with-ophthalmic-artery-chemosurgery-ocular-and-recurrence-free-survival
#3
Jasmine H Francis, Ariana M Levin, Emily C Zabor, Y Pierre Gobin, David H Abramson
PURPOSE: To report associations between disease- and treatment-related variables and rates of recurrence-free survival and ocular survival in eyes treated with ophthalmic artery chemosurgery (OAC) for retinoblastoma. DESIGN: Pre-post study. SUBJECTS: All eyes treated with OAC for retinoblastoma at Memorial Sloan Kettering Cancer Center between May 2006 and February 2017. METHODS: This retrospective review included 452 retinoblastoma eyes treated with OAC...
2018: PloS One
https://www.readbyqxmd.com/read/29790979/petrosal-meningiomas-factors-affecting-outcome-and-the-role-of-intraoperative-multimodal-assistance-to-microsurgery
#4
Francesco Tomasello, Filippo Flavio Angileri, Alfredo Conti, Antonino Scibilia, Salvatore Cardali, Domenico La Torre, Antonino Germanò
BACKGROUND: Petrous meningiomas (PMs) represent a subset of posterior fossa tumors accounting for ∼8% of all intracranial meningiomas. Surgical treatment of PMs is challenging because of their relationships with vital neurovascular structures of the cerebellopontine angle. OBJECTIVE: To investigate independent pre- and intraoperative predictors of PM surgery outcome. METHODS: We reviewed the surgical and outcome data of patients who underwent microsurgical resection of PMs from 1997 to 2016...
May 22, 2018: Neurosurgery
https://www.readbyqxmd.com/read/29790694/advances-in-antibody-therapeutics-targeting-small-cell-lung-cancer
#5
REVIEW
Hongyang Lu, Zhiming Jiang
The proportion of small-cell lung cancer (SCLC) among all lung cancers decreased from 17.26% in 1986 to 12.95% in 2002. Chemotherapy is the key mode of treatment. However, novel therapeutic strategies and drugs are imperative, as the prognosis remains poor. In recent years, antibody therapies have shown promising prospects against malignancy. This review focuses on the advances in antibody therapies in SCLC. Although the results of pembrolizumab, nivolumab, ipilimumab, and rovalpituzumab tesirine are inspiring, all of the clinical trials on these drugs are phase I/II and have been verified for further phase III clinical trials...
May 16, 2018: Advances in Clinical and Experimental Medicine: Official Organ Wroclaw Medical University
https://www.readbyqxmd.com/read/29790675/loss-of-cyclin-dependent-kinase-like-2-predicts-poor-prognosis-in-gastric-cancer-and-its-overexpression-suppresses-cells-growth-and-invasion
#6
Chia-Lang Fang, Yih-Huei Uen, Han-Kun Chen, You-Cheng Hseu, Chih-Chan Lin, Shih-Ting Hung, Ding-Ping Sun, Kai-Yuan Lin
Cyclin-dependent kinase-like 2 (CDKL2), a new member of the cyclin-dependent kinase family, may be involved in gastric cancer (GC) progression. Thus, we conducted this study to explore the clinical effect of CDKL2 in GC. Immunohistochemistry was used to measure CDKL2 levels in gastric tissues. The association of a high CDKL2 level with clinical and pathological characteristics, and the correlation between the CDKL2 level and disease-free and overall survival were analyzed. Transfection was employed to overexpress CDKL2 in GC cells and to investigate the effect of CDKL2 overexpression on cell proliferation and invasion...
May 23, 2018: Cancer Medicine
https://www.readbyqxmd.com/read/29790149/survival-after-secondary-cytoreductive-surgery-and-chemotherapy-compared-with-chemotherapy-alone-for-first-recurrence-in-patients-with-platinum-sensitive-epithelial-ovarian-cancer-and-no-residuals-after-primary-treatment-a-registry-based-study
#7
Witold Szczesny, Hilde Langseth, Tor Å Myklebust, Janne Kaern, Claes Tropé, Torbjørn Paulsen
INTRODUCTION: To investigate whether secondary cytoreductive surgery and platinum-based chemotherapy improved survival among patients with recurrent, platinum-sensitive epithelial ovarian cancer compared with those who received platinum-based chemotherapy alone, and to identify possible predictors for selection to secondary cytoreductive surgery. MATERIAL AND METHODS: We included 397 patients who had a primary diagnosis of FIGO stage I-IV epithelial ovarian cancer recorded in the Cancer Registry of Norway between 1 January 2002 and 31 December 2012, received primary surgery with no residuals followed by platinum-based chemotherapy, had first recurrence six or more months after completion of primary platinum-based chemotherapy, and received secondary treatment with either secondary cytoreductive surgery and platinum-based chemotherapy (secondary cytoreductive surgery+platinum-based chemotherapy group) or platinum-based chemotherapy alone (platinum-based chemotherapy group)...
May 22, 2018: Acta Obstetricia et Gynecologica Scandinavica
https://www.readbyqxmd.com/read/29790064/cohort-study-on-prognosis-of-patients-with-metastatic-colorectal-cancer-treated-with-integrated-chinese-and-western-medicine
#8
Tong Zhang, Wen-Ting He, Ming-Jie Zi, Gang Song, Dan-Hui Yi, Yu-Fei Yang
OBJECTIVE: To investigate the efficacy of integrated Chinese and Western medicine (IM) in the treatment of metastatic colorectal cancer (mCRC) in a cohort study. METHODS: The survival outcome of patients receiving IM was compared with that of patients receiving Western medicine alone. The study design was adopted with "continuous administration of Chinese medicine for ⩾ 3 months" as the exposure factor. Patients who met this exposure factor were assigned to the IM cohort (Group A, 110 patients)...
May 22, 2018: Chinese Journal of Integrative Medicine
https://www.readbyqxmd.com/read/29790020/can-we-accurately-predict-cost-effectiveness-without-access-to-overall-survival-data-the-case-study-of-nivolumab-in-combination-with-ipilimumab-for-the-treatment-of-patients-with-advanced-melanoma-in-england
#9
D Lee, A Amadi, J Sabater, J Ellis, H Johnson, S Kotapati, S McNamara, A Walker, M Cooper, K Patterson, N Roskell, Y Meng
BACKGROUND: Nivolumab with ipilimumab (the Regimen) is the first immuno-oncology combination treatment to demonstrate long-term clinical benefit for advanced melanoma patients. We evaluated the cost effectiveness of the Regimen in this population, with and without the availability of overall survival (OS) data. METHODS: A partitioned survival model and a Markov state-transition model were developed to estimate the lifetime costs and benefits of the Regimen versus ipilimumab...
May 22, 2018: PharmacoEconomics Open
https://www.readbyqxmd.com/read/29790004/exploring-sex-specific-differences-in-the-presentation-and-outcomes-of-anca-associated-vasculitis-a-nationwide-registry-based-cohort-study
#10
Rune Bjørneklett, Vilde Solbakken, Leif Bostad, Anne-Siri Fismen
PURPOSE: Sex-specific differences in the risk of end-stage renal disease (ESRD) in patients with anti-neutrophil cytoplasmic antibody-associated glomerulonephritis (ANCA-GN) stratified by histological classification have not been previously investigated. METHODS: Patients with biopsy-verified pauci-immune necrotizing GN and positive ANCA serology in the Norwegian Kidney Biopsy Registry between 1991 and 2012 were included. Patients with ESRD during follow-up were identified from the Norwegian Renal Registry...
May 22, 2018: International Urology and Nephrology
https://www.readbyqxmd.com/read/29789969/identification-of-risk-factors-for-toxicity-in-patients-with-hormone-receptor-positive-advanced-breast-cancer-treated-with-bevacizumab-plus-letrozole-a-calgb-40503-alliance-correlative-study
#11
Daneng Li, Linda M McCall, Olwen M Hahn, Clifford A Hudis, Harvey J Cohen, Hyman B Muss, Aminah Jatoi, Jacqueline M Lafky, Karla V Ballman, Eric P Winer, Debu Tripathy, Bryan Schneider, William Barry, Maura N Dickler, Arti Hurria
BACKGROUND: In hormone receptor-positive advanced breast cancer, a progression-free survival benefit was reported with addition of bevacizumab to first-line letrozole. However, increased toxicity was observed. We hypothesized that functional age measures could be used to identify patients at risk for toxicity while receiving letrozole plus bevacizumab for hormone receptor-positive advanced breast cancer. METHODS: CALGB 40503 was a phase III trial that enrolled patients with hormone receptor-positive advanced breast cancer randomized to letrozole with or without bevacizumab...
May 22, 2018: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/29789762/percutaneous-computed-tomography-guided-permanent-125-i-implantation-as-therapy-for-pulmonary-metastasis
#12
Xiaodong Huo, Bin Huo, Huixing Wang, Lei Wang, Qiang Cao, Guangjun Zheng, Junjie Wang, Shude Chai, Zuncheng Zhang, Kuo Yang, Yuanjie Niu, Haitao Wang
Purpose: To evaluate intermediate-term outcomes after computed tomography (CT)-guided radioactive 125 I seed implantation (CTRISI), and to determine prognostic variables associated with outcomes in patients with pulmonary metastases. Material and methods: Thoracic surgeons evaluated and performed implantation of 125 I radioactive seeds under CT guidance or combined with surgical resection. Patients were monitored in the thoracic surgery clinic for recurrence and survival...
April 2018: Journal of Contemporary Brachytherapy
https://www.readbyqxmd.com/read/29789718/pdlim7-and-cdh18-regulate-the-turnover-of-mdm2-during-cdk4-6-inhibitor-therapy-induced-senescence
#13
Mary E Klein, Mark A Dickson, Cristina Antonescu, Li-Xuan Qin, Scott J Dooley, Afsar Barlas, Katia Manova, Gary K Schwartz, Aimee M Crago, Samuel Singer, Andrew Koff, William D Tap
CDK4/6 inhibitors are being used to treat a variety of human malignancies. In well-differentiated and dedifferentiated liposarcoma their clinical promise is associated with their ability to downregulate the MDM2 protein. The downregulation of MDM2 following treatment with CDK4/6 inhibitors also induces many cultured tumor cell lines derived from different types of malignancies to progress from quiescence into senescence. Here we used cultured human cell lines and defined a role for PDLIM7 and CDH18, regulating MDM2 protein in CDK4/6 inhibitor-treated cells...
May 23, 2018: Oncogene
https://www.readbyqxmd.com/read/29789714/estrogen-receptor-%C3%AE-promotes-renal-cell-carcinoma-progression-via-regulating-lncrna-hotair-mir-138-200c-204-217-associated-cerna-network
#14
Jie Ding, Chiuan-Ren Yeh, Yin Sun, Changyi Lin, Joshua Chou, Zhenyu Ou, Chawnshang Chang, Jun Qi, Shuyuan Yeh
Recent studies indicated that the estrogen receptor beta (ERβ) could affect the progression of prostate and bladder tumors, however, its roles in the renal cell carcinoma (RCC), remain to be elucidated. Here, we provide clinical evidence that ERβ expression is correlated in a negative manner with the overall survival/disease-free survival in RCC patients. Mechanism dissection revealed that targeting ERβ with ERβ-shRNA and stimulating the transactivation of ERβ with 17β-estradiol or environmental endocrine disrupting chemicals, all resulted in altering the lncRNA HOTAIR expression...
May 23, 2018: Oncogene
https://www.readbyqxmd.com/read/29789013/prognostic-significance-of-pd-l1-expression-and-cd8-t-cell-infiltration-in-pulmonary-neuroendocrine-tumors
#15
Haiyue Wang, Zhongwu Li, Bin Dong, Wei Sun, Xin Yang, Ruping Liu, Lixin Zhou, Xiaozheng Huang, Ling Jia, Dongmei Lin
BACKGROUND: Recent research supports a significant role of immune checkpoint inhibitors in the treatment of solid tumors. However, relevant reports for programmed death-ligand 1 (PD-L1) and CD8+ tumor-infiltrating lymphocytes (TILs) in pulmonary neuroendocrine tumors (PNETs) have not been fully studied. Therefore, we investigated PNETs for the expression of PD-L1 and infiltration by CD8+ TILs as well as the prognostic value of both factors. METHODS: In total, 159 specimens of PNETs (35 TC, 2 AC, 28 LCNEC, 94 SCLC) were included in this study...
May 22, 2018: Diagnostic Pathology
https://www.readbyqxmd.com/read/29788322/outcomes-and-risk-factors-associated-with-tricuspid-valve-repair-in-children-with-hypoplastic-left-heart-syndrome
#16
Bahaaldin Alsoufi, Raina Sinha, Courtney McCracken, Janet Figueroa, Firat Altin, Kirk Kanter
OBJECTIVES: Tricuspid valve (TV) competence is important for successful palliation of hypoplastic left heart syndrome (HLHS). We report our experience with TV repair in HLHS patients with a focus on TV and right ventricular (RV) function and associated clinical outcomes. METHODS: From 2002 to 2012, 219 neonates with HLHS underwent the Norwood operation. Thirty patients who underwent TV repair at various stages comprised our current series cohort. Echocardiographic and clinical data were reviewed to determine the effectiveness of TV repair and outcomes of the patients...
May 19, 2018: European Journal of Cardio-thoracic Surgery
https://www.readbyqxmd.com/read/29788164/what-is-the-optimal-systemic-treatment-of-men-with-metastatic-hormone-naive-prostate-cancer-a-stopcap-systematic-review-and-network-meta-analysis
#17
C L Vale, D J Fisher, I R White, J R Carpenter, S Burdett, N W Clarke, K Fizazi, G Gravis, N D James, M D Mason, M K B Parmar, L H Rydzewska, C J Sweeney, M R Spears, M R Sydes, J F Tierney
Background: Our prior Systemic Treatment Options for Cancer of the Prostate systematic reviews showed improved survival for men with metastatic hormone-naive prostate cancer when abiraterone acetate plus prednisolone/prednisone (AAP) or docetaxel (Doc), but not zoledronic acid (ZA), were added to androgen-deprivation therapy (ADT). Trial evidence also suggests a benefit of combining celecoxib (Cel) with ZA and ADT. To establish the optimal treatments, a network meta-analysis (NMA) was carried out based on aggregate data (AD) from all available studies...
May 1, 2018: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/29788041/do-older-and-younger-patients-derive-similar-survival-benefits-from-novel-oncology-drugs-a-systematic-review-and-meta-analysis
#18
Vanessa S Arciero, Sierra Cheng, Robert Mason, Erica McDonald, Ronak Saluja, Kelvin K W Chan
Background: older patients are commonly believed to derive less benefit from cancer drugs, even if they fulfil clinical trial eligibility [Talarico et al. (2004, J Clin Oncol, 22(22):4626-31)]. We aim to examine if novel oncology drugs provide differential age-based treatment outcomes for patients on clinical trials. Methods: a systematic review of randomised control trials (RCTs) cited for clinical efficacy evidence in novel oncology drug approvals by the Food and Drug Administration, European Medicines Agency and Health Canada between 2006 and 2017 was conducted...
May 19, 2018: Age and Ageing
https://www.readbyqxmd.com/read/29785861/prognostic-importance-of-albumin-to-globulin-ratio-in-metastatic-gastric-cancer-patients
#19
Yakup Bozkaya, Gökmen Umut Erdem, Nebi Serkan Demirci, Ozan Yazıcı, Nuriye Yıldırım Özdemir, Osman Köstek, Nurullah Zengin
AIM: The aim of this study was to evaluate the prognostic importance of albumin to globulin ratio (AGR) in terms of overall survival (OS) and progression free survival (PFS) in metastatic gastric cancer patients. METHODS: The patients diagnosed with metastatic gastric cancer between 2009 and April 2016 at our hospital have been studied retrospectively. The clinicopathological characteristics, laboratory and treatment parameters have been assessed. AGR value has been calculated using the following formula (AGR = serum albumin/total protein-serum albumin)...
May 22, 2018: Current Medical Research and Opinion
https://www.readbyqxmd.com/read/29785761/a-novel-thyroid-function-index-associated-with-opposite-therapeutic-outcomes-in-advanced-hepatocellular-carcinoma-patients-receiving-chemotherapy-or-sorafenib
#20
Yu-De Chu, Kwang-Huei Lin, Ya-Hui Huang, Chen-Chun Lin, Chien-Fu Hung, Ta-Sen Yeh, Wei-Chen Lee, Chau-Ting Yeh
AIM: A sustained proportion of advanced hepatocellular carcinoma (HCC) patients worldwide received either chemotherapy or sorafenib. However, to date, effective and convenient biomarkers to predict their therapeutic outcomes remained elusive. Hypothyroidism was associated with favorable anticancer treatment outcomes in several advanced cancers. Here, we aimed to investigate the potential of using thyroid-stimulating hormone (TSH) and free T4 (FT4) levels as biomarkers to predict clinical outcomes in HCC patients receiving chemotherapy or sorafenib...
May 21, 2018: Asia-Pacific Journal of Clinical Oncology
keyword
keyword
119233
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"